Accuri C6 Flow Cytometer System
Originally published online as doi:10.1189/jlb.0304120 on May 20, 2004

Published online before print May 20, 2004
This Article
Right arrow Full Text Free
Right arrow Full Text (PDF) Free
Right arrow All Versions of this Article:
jlb.0304120v1
76/2/333    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Finkelstein, S. E.
Right arrow Articles by Restifo, N. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Finkelstein, S. E.
Right arrow Articles by Restifo, N. P.
(Journal of Leukocyte Biology. 2004;76:333-337.)
© 2004 by Society for Leukocyte Biology

Bedside to bench and back again: how animal models are guiding the development of new immunotherapies for cancer

Steven E. Finkelstein1, David M. Heimann, Christopher A. Klebanoff, Paul A. Antony, Luca Gattinoni, Christian S. Hinrichs, Leroy N. Hwang, Douglas C. Palmer, Paul J. Spiess, Deborah R. Surman, Claudia Wrzesiniski, Zhiya Yu, Steven A. Rosenberg and Nicholas P. Restifo1

National Cancer Institute, National Institutes of Health, Surgery Branch, Bethesda, Maryland

1Correspondence: Surgery Branch, National Cancer Institute, National Institutes of Health, Building 10, Room 2B-46, 10 Center Drive, Bethesda, MD 20892. E-mail: Steven_Finkelstein{at}nih.gov and Nicholas_Restifo{at}nih.gov

Immunotherapy using adoptive cell transfer is a promising approach that can result in the regression of bulky, invasive cancer in some patients. However, currently available therapies remain less successful than desired. To study the mechanisms of action and possible improvements in cell-transfer therapies, we use a murine model system with analogous components to the treatment of patients. T cell receptor transgenic CD8+ T cells (pmel-1) specifically recognizing the melanocyte differentiation antigen gp100 are adoptively transferred into lympho-depleted mice bearing large, established, 14-day subcutaneous B16 melanoma (0.5–1 cm in diameter) on the day of treatment. Adoptive cell transfer in combination with interleukin interleukin-2 or interleukin-15 cytokine administration and vaccination using an altered form of the target antigen, gp100, can result in the complete and durable regression of large tumor burdens. Complete responders frequently develop autoimmunity with vitiligo at the former tumor site that often spreads to involve the whole coat. These findings have important implications for the design of immunotherapy trials in humans.

Key Words: IFN-{gamma} • MHC • interleukin • melanoma • adoptive cell transfer • vaccination • active immunization • cytokine • tumor




This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
L. Wang, W. Wen, J. Yuan, B. Helfand, Y. Li, C. Shi, F. Tian, J. Zheng, F. Wang, L. Chen, et al.
Immunotherapy for Human Renal Cell Carcinoma by Adoptive Transfer of Autologous Transforming Growth Factor {beta}-Insensitive CD8+ T Cells
Clin. Cancer Res., January 1, 2010; 16(1): 164 - 173.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
W. K. Nevala, C. M. Vachon, A. A. Leontovich, C. G. Scott, M. A. Thompson, S. N. Markovic, and for the Melanoma Study Group of the Mayo Clinic Ca
Evidence of Systemic Th2-Driven Chronic Inflammation in Patients with Metastatic Melanoma
Clin. Cancer Res., March 15, 2009; 15(6): 1931 - 1939.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
A. Song, X. Tang, K. M. Harms, and M. Croft
OX40 and Bcl-xL Promote the Persistence of CD8 T Cells to Recall Tumor-Associated Antigen
J. Immunol., September 15, 2005; 175(6): 3534 - 3541.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
M. R. Raspollini, F. Castiglione, D. Rossi Degl'Innocenti, G. Amunni, A. Villanucci, F. Garbini, G. Baroni, and G. L. Taddei
Tumour-infiltrating gamma/delta T-lymphocytes are correlated with a brief disease-free interval in advanced ovarian serous carcinoma
Ann. Onc., April 1, 2005; 16(4): 590 - 596.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
Q. Zhang, X. Yang, M. Pins, B. Javonovic, T. Kuzel, S.-J. Kim, L. V. Parijs, N. M. Greenberg, V. Liu, Y. Guo, et al.
Adoptive Transfer of Tumor-Reactive Transforming Growth Factor-{beta}-Insensitive CD8+ T Cells: Eradication of Autologous Mouse Prostate Cancer
Cancer Res., March 1, 2005; 65(5): 1761 - 1769.
[Abstract] [Full Text] [PDF]

Home page
 JEMHome page
R. Zeng, R. Spolski, S. E. Finkelstein, S. Oh, P. E. Kovanen, C. S. Hinrichs, C. A. Pise-Masison, M. F. Radonovich, J. N. Brady, N. P. Restifo, et al.
Synergy of IL-21 and IL-15 in regulating CD8+ T cell expansion and function
J. Exp. Med., January 3, 2005; 201(1): 139 - 148.
[Abstract] [Full Text] [PDF]